Clinical trial
Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With…
NCT00012324 · Eximias Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00012324 |
|---|---|
| Title | Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer |
| Official title | A Phase III Randomized Controlled Study Comparing the Survival of Patients With Unresectable Hepatocellular Carcinoma (HCC) Treated With THYMITAQ to Patients Treated With Doxorubicin |
| Lead sponsor | Eximias Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug |
| Interventions | doxorubicin hydrochloride, nolatrexed dihydrochloride |
| Start date | Sep 1, 2000 |
| Completion | Nov 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 26, 2013 |
| Countries | Canada, Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: